Why Parents Are Waking Up at 5AM and the Brand That's Trying to Help
That's where Tucksy comes in — a sleep wellness resource built for the early years. Tucksy focuses on baby sleep from birth through toddlerhood, helping families navigate short naps, early wakes, changing routines, and the constant guessing game of how much sleep is 'enough.'
At the heart of it is a weekly email guide matched to each baby's age. Unlike rigid sleep training programs or overwhelming expert advice, Tucksy offers calm design, real-life routines, and the kind of words parents need at 5AM when nothing's going to plan.
"We are not just here to talk about sleep. We are here to support parents through the emotional weight of it," says the team behind Tucksy. "Because the hardest hours are not always at night. Sometimes, they begin just after dawn."
Every Tucksy email blends expert-backed tips, gentle language, and practical tools for the stage a baby is in and the state a parent is in. Think of it as a weekly check-in that feels like a deep breath in your inbox. The content is age-based, free to access, and designed for real life. There's no judgment, no pressure, and no cry-it-out required.
Tucksy is also introducing calming audio content under the name Tucksy Sleep, including sleep sounds and bedtime stories that offer soft support for babies and parents alike.
"Parents do not need perfection. They need a sense of calm, a little clarity, and the quiet feeling that someone understands," the Tucksy team adds.
About Tucksy
Tucksy is a modern sleep wellness brand for parents and their babies. From birth to age seven, Tucksy offers expert-curated weekly email guides, soothing digital content, and small comforts to help families sleep better and grow stronger together. Learn more at tucksy.com.
Media Contact
Company Name: Tucksy
Email: Send Email
Country: United States
Website: https://tucksy.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
9 hours ago
- CTV News
Family awaiting donor holds on to hope, spreads word
Calgary Watch An Airdrie couple is spreading the word about live liver donation, as they await a donor to save their toddler's life and help other kids on the waitlist.
Globe and Mail
9 hours ago
- Globe and Mail
Anal Cancer Pipeline Outlook Report 2025: Key 6+ Companies and Breakthrough Therapies Shaping the Future Landscape
DelveInsight's, 'Anal Cancer Pipeline Insight 2025' report provides comprehensive insights about 6+ companies and 8+ pipeline drugs in Anal Cancer pipeline landscape. It covers the Anal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Anal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Anal Cancer Pipeline Report to explore emerging therapies, key companies, and future treatment landscapes @ Anal Cancer Pipeline Outlook Report Key Takeaways from the Anal Cancer Pipeline Report In July 2025, Incyte Corporation announced a Phase 3 global, multicenter, placebo-controlled double-blind randomized study that will enroll participants with inoperable locally recurrent or metastatic SCAC not previously treated with systemic chemotherapy. In July 2025, Merck Sharp & Dohme LLC conducted a study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors who have progressed on standard of care therapy will be treated with pembrolizumab (MK-3475). DelveInsight's Anal Cancer pipeline report depicts a robust space with 6+ active players working to develop 8+ pipeline therapies for Anal Cancer treatment. The leading Anal Cancer Companies such as Incyte Corporation, Merck & Co., Novartis Pharmaceuticals, Advaxis and others. Promising Anal Cancer Pipeline Therapies such as VGX-3100, HPV-16 vaccine, Pembrolizumab, Paclitaxel, Carboplatin, MPDL3280A, Cisplatin, V503, Axalimogene filolisbac and others. Discover how the Anal Cancer treatment paradigm is evolving. Access DelveInsight's in-depth Anal Cancer Pipeline Analysis for a closer look at promising breakthroughs @ Anal Cancer Clinical Trials and Studies Anal Cancer Emerging Drugs Profile PDS0101: Merck & Co PDS0101 is a novel investigational human papillomavirus (HPV)-targeted immunotherapy that stimulates a potent targeted T cell attack against HPV-positive cancers. PDS0101 is given by a simple subcutaneous injection in combination with other immunotherapies and cancer treatments. Interim data suggests PDS0101 generates clinically effective immune responses, and the combination of PDS0101 with other treatments demonstrates significant disease control by shrinking tumors, delaying disease progression, and/or prolonging survival. The combination of PDS0101 with other treatments does not appear to compound the toxicity of other agents. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of patients with anal cancer. BMX-001: BioMimetix BMX-001 is a metalloporphyrin, a novel class of redox-active, small molecule. The active center is designed to mimic the center of superoxide dismutase. The primary mechanism of action is modulation of cellular signaling pathways. BMX-001 inhibits both NFkB and HIF-1a. By inhibiting these pro-survival and pro-angiogenic transcription factors, BMX-001 augments tumor killing by radiation therapy and inhibits tumor regrowth. The inhibition of NFkB blocks major components of the inflammatory cascade which simultaneously results in protection of normal tissue from radiation induced injury. The drug is in phase I/II of clinical trials for the treatment of anal cancer. The Anal Cancer Pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Anal Cancer with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Anal Cancer Treatment. Anal Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Anal Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Anal Cancer market. Get a detailed analysis of the latest innovations in the Anal Cancer pipeline. Explore DelveInsight's expert-driven report today! @ Anal Cancer Unmet Needs Anal Cancer Companies Incyte Corporation, Merck & Co., Novartis Pharmaceuticals, Advaxis and others. Anal Cancer Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Anal Cancer Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Download DelveInsight's latest report to gain strategic insights into upcoming Anal Cancer Therapies and key Developments @ Anal Cancer Market Drivers and Barriers, and Future Perspectives Scope of the Anal Cancer Pipeline Report Coverage- Global Anal Cancer Companies- Incyte Corporation, Merck & Co., Novartis Pharmaceuticals, Advaxis and others. Anal Cancer Pipeline Therapies- VGX-3100, HPV-16 vaccine, Pembrolizumab, Paclitaxel, Carboplatin, MPDL3280A, Cisplatin, V503, Axalimogene filolisbac and others. Anal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Anal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Which companies are leading the race in Anal Cancer drug development? Find out in DelveInsight's exclusive Anal Cancer Pipeline Report—access it now! @ Anal Cancer Emerging Drugs and Major Companies Table of Contents Introduction Executive Summary Anal Cancer: Overview Pipeline Therapeutics Therapeutic Assessment Anal Cancer– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Retifanlimab: Incyte Corporation Mid Stage Products (Phase II) PDS0101: Merck & Co Early Stage Products (Phase I) Drug Name: Company Name Preclinical and Discovery Stage Products Drug name: Company name Inactive Products Anal Cancer Key Companies Anal Cancer Key Products Anal Cancer- Unmet Needs Anal Cancer- Market Drivers and Barriers Anal Cancer- Future Perspectives and Conclusion Anal Cancer Analyst Views Anal Cancer Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
9 hours ago
- Globe and Mail
Pulmonary Fibrosis Pipeline Outlook Report 2025: Key 110+ Companies and Breakthrough Therapies Shaping the Future Landscape
DelveInsight's, 'Pulmonary Fibrosis Pipeline Insight 2025' report provides comprehensive insights about 110+ companies and 140+ pipeline drugs in Pulmonary Fibrosis pipeline landscape. It covers the Pulmonary Fibrosis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Pulmonary Fibrosis Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Pulmonary Fibrosis Pipeline. Dive into DelveInsight's comprehensive report today! @ Pulmonary Fibrosis Pipeline Outlook Key Takeaways from the Pulmonary Fibrosis Pipeline Report In August 2025, InSilico Medicine Hong Kong Limited announced a clinical trial is to learn about INS018_055 in adults with Idiopathic Pulmonary Fibrosis (IPF). The primary objective is to evaluate the safety and tolerability of INS018_055 orally administered for up to 12 weeks in adult subjects with IPF compared to placebo. In August 2025, Daewoong Pharmaceutical Co. Ltd conducted a phase 2 study to evaluate the Safety and Efficacy of DWN12088 in Patients With Idiopathic Pulmonary Fibrosis. DelveInsight's Pulmonary Fibrosis Pipeline report depicts a robust space with 110+ active players working to develop 140+ pipeline therapies for Pulmonary Fibrosis treatment. The leading Pulmonary Fibrosis Companies such as Bristol-Myers Squibb, Ark Biosciences Inc., PureTech Health, Sarepta Therapeutics, Toray Industries, Inc., Wuhan Optics Valley Vcanbiopharma Co., Ltd., Nitto Denko, Syndax Pharmaceuticals, Endeavor BioMedicines, AstraZeneca, Pulmongene Ltd., BreStem Therapeutics, Nuformix, AbbVie, Saniona and others. Promising Pulmonary Fibrosis Pipeline Therapies such as BMS-986278, Pirfenidone, Etanercept, BI 1839100, CNTO 888 1 mg/kg, Nintedanib, Pirfenidoneone and others. Stay ahead with the most recent pipeline outlook for Pulmonary Fibrosis. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Pulmonary Fibrosis Treatment Drugs Pulmonary Fibrosis Emerging Drugs Profile BMS-986278: Bristol-Myers Squibb BMS-986278 is a potential first-in-class, oral, small molecule lysophosphatidic acid receptor 1 (LPA1) antagonist currently being evaluated as a novel antifibrotic treatment for patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. Increased LPA levels and activation of LPA are involved in the pathogenesis of pulmonary fibrosis. BMS-986278 is a potent and complete antagonist of LPA action at LPA1-mediated Gi, Gq, G12, and β-arrestin signaling pathways in both cells heterologously expressing human LPA1 and in primary human lung fibroblasts. The drug is currently in Phase III stage of clinical trial evaluation for the treatment of pulmonary fibrosis. AK3280: Ark Biosciences Inc. AK3280 is a next-generation broad-spectrum anti-fibrotic molecule optimized from the marketed drug pirfenidone. It has the ability to modulate multiple pathways and biomarkers closely associated with the fibrotic process, including the expression of fibrosis-related genes and proteins induced by transforming growth factor-beta (TGF-B) and lysophosphatidic acid (LPA). AK3280 works by reducing cell proliferation and inhibiting the synthesis and accumulation of extracellular matrix. Compared to pirfenidone, AK3280 offers advantages in safety and tolerability, with potentially much better clinical efficacy. The drug is currently in Phase II stage of clinical trial evaluation for the treatment of pulmonary fibrosis. LYT-100: PureTech Health LYT-100 (deupirfenidone) is currently in development for idiopathic pulmonary fibrosis (IPF), which is a rare, progressive and fatal disease. LYT-100 is a deuterated form of pirfenidone and is designed to retain the beneficial pharmacology and clinically-validated efficacy of pirfenidone with a highly differentiated pharmacokinetic (PK) profile. In multiple clinical trials, LYT-100 has demonstrated a favorable tolerability profile, which may keep patients on treatment longer to enable more optimal disease management. The drug is currently in Phase II stage of clinical trial evaluation for the treatment of pulmonary fibrosis. ARO-MMP7: Sarepta Therapeutics ARO-MMP7 is an investigational RNA interference (RNAi) therapeutic developed by Arrowhead Pharmaceuticals, aimed at treating idiopathic pulmonary fibrosis (IPF) by targeting and reducing the expression of matrix metalloproteinase 7 (MMP7). This protein is implicated in the pathogenesis of IPF, contributing to inflammation and fibrosis in the lungs. The drug is currently in Phase I/II stage of clinical trial evaluation for the treatment of pulmonary fibrosis. TRK-250: Toray Industries, Inc TRK-250, also known as BNC-1021, is a nucleic acid medicine developed by Toray Industries in collaboration with BONAC Corporation. It is designed to treat Idiopathic Pulmonary Fibrosis (IPF). The drug works by selectively inhibiting the expression of transforming growth factor-beta 1 (TGF-β1), a key protein involved in the fibrotic process at the gene expression level. The drug is currently in Phase I stage of clinical trial evaluation for the treatment of pulmonary fibrosis. VUM02: Wuhan Optics Valley Vcanbiopharma Co., Ltd. VUM02 Injection is an innovative therapeutic product developed by Wuhan Optics Valley Vcanbiopharma Co., Ltd. It utilizes human umbilical cord-derived mesenchymal stem cells (hUCT-MSCs). The drug is currently in Phase I stage of clinical trial evaluation for the treatment of pulmonary fibrosis. The Pulmonary Fibrosis Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Pulmonary Fibrosis with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pulmonary Fibrosis Treatment. Pulmonary Fibrosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Pulmonary Fibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pulmonary Fibrosis market Explore groundbreaking therapies and clinical trials in the Pulmonary Fibrosis Pipeline. Access DelveInsight's detailed report now! @ New Pulmonary Fibrosis Drugs Pulmonary Fibrosis Companies Bristol-Myers Squibb, Ark Biosciences Inc., PureTech Health, Sarepta Therapeutics, Toray Industries, Inc., Wuhan Optics Valley Vcanbiopharma Co., Ltd., Nitto Denko, Syndax Pharmaceuticals, Endeavor BioMedicines, AstraZeneca, Pulmongene Ltd., BreStem Therapeutics, Nuformix, AbbVie, Saniona and others. Pulmonary Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Pulmonary Fibrosis Products have been categorized under various Molecule types such as Small molecule Monoclonal antibody Peptide Polymer Gene therapy Unveil the future of Pulmonary Fibrosis Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Pulmonary Fibrosis Market Drivers and Barriers Scope of the Pulmonary Fibrosis Pipeline Report Coverage- Global Pulmonary Fibrosis Companies- Bristol-Myers Squibb, Ark Biosciences Inc., PureTech Health, Sarepta Therapeutics, Toray Industries, Inc., Wuhan Optics Valley Vcanbiopharma Co., Ltd., Nitto Denko, Syndax Pharmaceuticals, Endeavor BioMedicines, AstraZeneca, Pulmongene Ltd., BreStem Therapeutics, Nuformix, AbbVie, Saniona and others. Pulmonary Fibrosis Pipeline Therapies - BMS-986278, Pirfenidone, Etanercept, BI 1839100, CNTO 888 1 mg/kg, Nintedanib, Pirfenidoneone and others. Pulmonary Fibrosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Pulmonary Fibrosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Pulmonary Fibrosis Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Pulmonary Fibrosis Companies, Key Products and Unmet Needs Table of Content Introduction Executive Summary Pulmonary Fibrosis: Overview Therapeutic Assessment Pulmonary Fibrosis– DelveInsight's Analytical Perspective Late Stage Products (Phase III) BMS-986278: Bristol-Myers Squibb Drug profiles in the detailed report….. Mid Stage Products (Phase II) AK3280: Ark Biosciences Inc. Drug profiles in the detailed report….. Early Stage Products (Phase I) VUM02: Wuhan Optics Valley Vcanbiopharma Co., Ltd. Drug profiles in the detailed report….. Preclinical and Discovery Stage Products RSBT 001: RS BioTherapeutics Drug profiles in the detailed report….. Inactive Products Pulmonary Fibrosis Key Companies Pulmonary Fibrosis Key Products Pulmonary Fibrosis- Unmet Needs Pulmonary Fibrosis- Market Drivers and Barriers Pulmonary Fibrosis- Future Perspectives and Conclusion Pulmonary Fibrosis Analyst Views Pulmonary Fibrosis Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
